FilingSEC EDGAR8-K
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 MIRACLE Trial
· SEC accepted
StagePhase 2/3
Filing content
The company completed enrollment for Part A of its Phase 2/3 MIRACLE trial for Annamycin and remains on track for a data readout in Q1 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…